AzTrials
AzTrials

Acute Coronary SyndromeTeleCorNCT04862026

Telemonitoring of Patients With Acute Coronary Syndrome

An observational study of Acute Coronary Syndrome, run by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department at 1 site in Russia.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

It is planned to enroll 950 patients in an open, prospective, randomized study to assess the impact of telemonitoring on the development of clinical events and improve the quality of life of patients with acute coronary syndrome. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Acute Coronary Syndrome
How many people
950 participants
Where
1 siteRussia
Study dates
29 Apr 2021to 1 Jun 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with acute coronary syndrome who have undergone the hospital stage of treatment are included in the study at the time of discharge. And then, at the outpatient stage after randomization, the first group receives standard assistance together with telemonitoring support, the second group - standard offline medical assistance.

Who may be able to join

  • Signed informed consent;
  • Age 18 - 80 years old.
  • Diagnosis:
  • Acute myocardial infarction (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9)
  • Unstable angina (I20.0) Recurrent myocardial infarction (I22.0, I22.1, I22.8, I22.9)

Who cannot join

  • Lack of technical equipment to connect to remote monitoring programs;
  • Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
  • Mental illness in the acute stage;
  • Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
  • Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
  • Participation in other clinical studies to assess the effectiveness of pharmacological drugs;
Show all 10Show fewer
  • Infection with SARS-CoV-2 with laboratory confirmation during the period of this study;
  • Acute coronary syndrome that developed in the hospital after surgery / intervention;
  • The emergence during observation of the need for surgical (not counting myocardial revascularization) or chemotherapy treatment;
  • Severe trauma (including craniocerebral) impeding observation according to the study protocol.

Trial locations and contacts

1 site in 1 country.

Russia1 site
  • City Clinical Hospital No. 13 of the Moscow City Health Department

    Moscow, 115280

Other trials in Russia

About this study

Official title: The Influence of Telemonitoring on the Development of Clinical Events and Improving the Quality of Life of Patients With Acute Coronary Syndrome (TeleCor)

It is planned to enroll 950 patients in an open, prospective, randomized study to assess the impact of telemonitoring on the development of clinical events and improve the quality of life of patients with acute coronary syndrome. The duration of the study is 365 days, of which 180 days are enrollment of patients, 180 days are observation. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test. The main objectives of the study are to study the effect of telemonitoring on mortality from cardiovascular diseases (CVD), as well as the number of readmissions for cardiovascular pathology in patients with ACS. The secondary endpoints of the study include quality of life as measured by the HeartQol questionnaire and adherence to ambulatory monitoring.

Read the detailed description

Purpose of the study: to study the effect of telemonitoring on the development of clinical events and improving the quality of life of patients with ACS.

Research objectives:

  1. Improving the effectiveness of medical care in patients who have undergone ACS: increasing the level of compliance of patients, increasing the level of medical awareness of patients, reducing the number of unmotivated requests for medical care, reducing the time to achieve the observed targets, reducing the proportion of complications, reducing the number of destabilizing conditions with further inpatient treatment, optimization of the workload on medical personnel.
  2. Creation of a unified methodology for remote observation using telemedicine technologies in patients with ACS.
  3. Creation of a unified model of remote nutrition correction in patients after ACS.

Number of volunteers: statistically equivalent groups by sex and age, 950 subjects (475 per group). The number of volunteers who completed the study was 712 subjects (75% of the total number of patients).

365 days: 6 months enrollment, 6 months follow-up.

Inclusion criteria:

  • Signed informed consent;
  • Age 18 - 80 years old.
  • Diagnosis:
  • Acute myocardial infarction (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9)
  • Unstable angina (I20.0) Recurrent myocardial infarction (I22.0, I22.1, I22.8, I22.9)

Exclusion criteria:

  • Lack of technical equipment to connect to remote monitoring programs;
  • Severe cognitive dysfunction - dementia leading to maladjustment in everyday life;
  • Mental illness in the acute stage;
  • Oncological diseases requiring radiation and chemotherapy during the period of this study, as well as the corresponding stages of T3-4N2-3M1;
  • Lack of technical ability to take part in telemonitoring (do not have the skills to work on a smartphone, computer, tablet, there is no appropriate technical means);
  • Participation in other clinical studies to assess the effectiveness of pharmacological drugs.

Exclusion criteria:

  • Infection with SARS-CoV-2 with laboratory confirmation during the period of this study;
  • Acute coronary syndrome that developed in the hospital after surgery / intervention;
  • The emergence during the observation of the need for surgical (not counting myocardial revascularization) or chemotherapy treatment;
  • Severe injuries (including craniocerebral), impeding observation according to the study protocol.

Primary endpoint (combined):

  1. a) Death from cardiovascular causes and / or b) Repeated hospitalizations for SS pathology
  2. The number of episodes requiring emergency or urgent care without hospitalization (calls to the emergency room for complaints from the cardiovascular system)

Secondary endpoints:

  1. Quality of life according to the HeartQol questionnaire.
  2. Commitment to outpatient monitoring - is determined by the number of participants who voluntarily left the study, by the percentage of results obtained - surveys in electronic form.
  3. Tolerance to physical activity (any increase in walking distance according to 6MWT, VEM according to indications).

Any decrease in body weight (weight, BMI) any decrease in waist circumference. The study of patients will include the collection of anamnesis, assessment of the clinical status of patients using special questionnaires, data of objective, laboratory and instrumental examinations. The instrumental complex of the examination will include: electrocardiography (ECG), 6-minute walk test (6MWT), Holter ECG monitoring (HMECG), echocardiography, veloergometry (VEM), assessment of the actual nutrition Nutrilogic, autogeneration of an individual diet (Nutrilogic), weekly telemonitoring. Laboratory examination includes: biochemical blood test.

Randomization by means of envelopes.

It is planned to create in advance a database of identification numbers (hereinafter - ID) in the amount corresponding to the planned set of patients (950 ID). Further, these numbers will be divided into two groups with an equal number of IDs in each:

  • Outpatient observation with connection to the telemonitoring program - 475 ID
  • Outpatient monitoring without connecting to the telemonitoring program - 475 ID Each ID number will be placed in an individual envelope and sealed. In accordance with the agreement on the number of patients to be included in the study, each specific healthcare facility will be provided with sealed envelopes in the required volume, taking into account the equal distribution of volunteers into 2 groups. After opening the envelope, the patient is assigned this ID, and the patient is assigned to the corresponding ID group.
Keywords
Acute coronary syndrome, telemonitoring
Medical subject headings
Acute Coronary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04862026
Study groupRoleWhat they receive
Telemonitoring groupThe telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments.
Control groupPatients with standard administration.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Death or rehospitalizations Primary endpoint A

    Death from cardiovascular causes and / or rehospitalizations for cardiovascular pathology

    Measured: Upon completion, up to 6 months

  2. Emergency or urgent care without hospitalization

    The number of episodes requiring emergency or urgent care without hospitalization (calls to the ambulance for complaints from the cardiovascular system)

    Measured: Upon completion, up to 6 months

Secondary outcomes (4)
  1. Quality of life according to the HeartQol questionnaire.

    Health-related quality of life, symptoms, and functional status make up patient-reported outcomes

    Measured: Upon completion, up to 6 months

  2. Commitment to outpatient monitoring

    Commitment to outpatient monitoring - is determined by the number of participants who voluntarily left the study, by the percentage of results obtained - surveys in electronic form.

    Measured: Upon completion, up to 6 months

  3. Tolerance to physical activity

    Tolerance to physical activity (any increase in walking distance according to 6MWT, VEM according to indications).

    Measured: Upon completion, up to 6 months

  4. Decrease in body weight

    Any decrease in body weight (weight, BMI) any decrease in waist circumference.

    Measured: Upon completion, up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2021
  2. Study start29 Apr 2021
  3. Primary completion6 Apr 2023
  4. Study completion1 Jun 2025 (estimated)

Why it stopped: Technical difficulties of the developer

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
950 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04862026
Sponsor's protocol ID
2021-1
Acronym
TeleCor
Status last verified
Apr 2023
First submitted
14 Apr 2021
Last updated
10 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Coronary Syndrome, run by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 10 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Death or rehospitalizations Primary endpoint A (time frame: Upon completion, up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in